Terns Pharmaceuticals’ stock surged after its experimental obesity drug, TERN-601, demonstrated promising weight loss results in a Phase I study. The drug showed dose-dependent weight reduction and a favorable safety profile, prompting the company to initiate a Phase II trial in 2025.
The Dow Jones Industrial Average surged by over 400 points on Monday, driven by positive news from several companies. Terns Pharmaceuticals shares jumped over 20% after announcing promising data from its Phase 1 trial for a new obesity treatment. Other notable gains came from Summit Therapeutics, Relay Therapeutics, ADMA Biologics, and more.
